磷脂酰肌醇蛋白聚糖3(GPC3)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法)
ELISA Kit for Glypican 3 (GPC3)
DGSX; OCI5; SDYS; SGB; SGBS1; MXR7; Glypican Proteoglycan 3; GTR2-2; Intestinal protein OCI-5; Secreted glypican-3
- 編號SEA971Mu
- 物種Mus musculus (Mouse，小鼠)相同的名稱，不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時(shí)長3h
- 檢測范圍13.7-10,000pg/mL
- 靈敏度最小可檢測劑量小于等于5.2pg/mL.
- 樣本類型Tissue homogenates, cell lysates and other biological fluids
- 下載英文說明書 中文說明書
- 規(guī)格48T96T96T*596T*1096T*100
- 價(jià)格¥ 2722¥ 3888¥ 17496¥ 33048¥ 272160
- 欲了解實(shí)際交易價(jià)格和更多情況，請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
產(chǎn)品包裝(模擬)
產(chǎn)品包裝(模擬)
實(shí)驗(yàn)結(jié)果圖
標(biāo)準(zhǔn)曲線圖
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測磷脂酰肌醇蛋白聚糖3(GPC3)，經(jīng)檢測與其它相似物質(zhì)無明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來源的限制，不可能完成對所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測，因此本試劑盒有可能與未經(jīng)檢測的其它物質(zhì)有交叉反應(yīng)。
精密度
精密度用樣品測定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對低、中、高值定值樣本進(jìn)行定量檢測,每份樣本連續(xù)測定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個(gè)不同批次的試劑盒分別對低、中、高值定值樣本進(jìn)行定量測定，每個(gè)樣本使用同一試劑盒重復(fù)測定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
穩(wěn)定性
經(jīng)測定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對試劑盒破壞前后檢測值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本的準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品及樣本）100µL，37°C孵育1小時(shí)；
3. 吸棄，加檢測溶液A100µL，37°C孵育1小時(shí)；
4. 洗板3次；
5. 加檢測溶液B100µL，37°C孵育30分鐘；
6. 洗板5次；
7. 加TMB底物90µL，37°C孵育10-20分鐘；
8. 加終止液50µL，立即450nm讀數(shù)。
實(shí)驗(yàn)原理
將磷脂酰肌醇蛋白聚糖3(GPC3)抗體包被于96孔微孔板中，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本，其中的磷脂酰肌醇蛋白聚糖3(GPC3)與連接于固相載體上的抗體結(jié)合，然后加入生物素化的磷脂酰肌醇蛋白聚糖3(GPC3)抗體，將未結(jié)合的生物素化抗體洗凈后，加入HRP標(biāo)記的親和素，再次徹底洗滌后加入TMB底物顯色。TMB在過氧化物酶的催化下轉(zhuǎn)化成藍(lán)色，并在酸的作用下轉(zhuǎn)化成最終的黃色。顏色的深淺和樣品中的磷脂酰肌醇蛋白聚糖3(GPC3)呈正相關(guān)。用酶標(biāo)儀在450nm波長下測定吸光度(O.D.值)，計(jì)算樣品濃度。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號 | 適用物種：Mus musculus (Mouse，小鼠) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| RPA971Mu01 | 磷脂酰肌醇蛋白聚糖3(GPC3)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| APA971Mu01 | 磷脂酰肌醇蛋白聚糖3(GPC3)活性蛋白 | Cell?culture;?Activity?Assays. |
| PAA971Mu01 | 磷脂酰肌醇蛋白聚糖3(GPC3)多克隆抗體 | WB; IHC. |
| SEA971Mu | 磷脂酰肌醇蛋白聚糖3(GPC3)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Nature and Science | Diagnostic Role of Serum Glypican-3 as a Tumor Marker for Hepatocellular Carcinoma [Sciencepub:10043238] |
| Journal of Applied Pharmaceutical Science | Cytotoxic effects of antiglypican-3 against HepG2 cell line[Ebscohost: Source] |
| Asian Pacific Journal of Cancer Prevention | Can Glypican3 be Diagnostic for Early Hepatocellular Carcinoma among Egyptian Patients?[Pubmed: 24460300] |
| Clin Biochem. | Diagnostic accuracy of serum glypican-3 for hepatocellular carcinoma: A systematic review and meta-analysis[Pubmed: 24362268] |
| Science and Nature | Diagnostic Role of Serum Glypican-3 as Hepatocellular Carcinoma[Zolcat: Source] |
| Alexandria Journal of Medicine | Role of serum glypican-3 in the diagnosis and differentiation of small hepatocellular carcinoma from hepatitis-C virus cirrhosis[ScienceDirect: S2090506814000062] |
| J Egypt Natl Canc Inst. | Comparing prothrombin induced by vitamin K absence-II (PIVKA-II) with the oncofetal proteins glypican-3, Alpha feto protein and carcinoembryonic antigen in diagnosing hepatocellular carcinoma among Egyptian patients.[Pubmed:24841158] |
| European Journal of Pharmacology | Evaluation of antiglypican-3 therapy as a promising target for amelioration of hepatic tissue damage in hepatocellular carcinoma[Pubmed:25449037] |
| Hepatobiliary Pancreat Dis Int | Predictive value of tumor markers in patients with recurrent hepatocellular carcinoma in different vascular invasion pattern[abstract:abstract4525.shtml] |
| Clinical?and Molecular Hepatology? | Glypican-3 level assessed by the enzyme-linked immunosorbent assay is inferior to alpha-fetoprotein level for hepatocellular carcinoma diagnosis[pmc:articles] |
| Wiley | Glypican‐3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment[pubmed:28621802] |
| Biomedicine & Pharmacotherapy | Cytotoxic and partial hepatoprotective activity of sodium ascorbate against hepatocellular carcinoma through inhibition of sulfatase-2 and[Pubmed:29669302] |
| Journal of Cancer and Clinical Oncology | Development and Validation of a Two-Site Immunoradiometric assay for Glypican-3 in plasma: Implication in Diagnosis of Hepatocellular Carcinoma[Researchgate:Source] |
| Turkish?journal?of?oncology | Serum Glypican-3, Vascular Endothelial Growth Factor, and Interleukin-6 Levels in Hepatocellular Carcinoma[10.5505:tjo.2018.1742] |
| Intensive?Care?Medicine?Experimental | Elevated plasma glypicans are associated with organ failure in patients with infection[Pubmed: 30618011] |
| VALUE OF SERUM GLYPICAN 3 AS A PREDICTIVE TOOL FOR EARLY DIAGNOSIS OF HEPATOCELLULAR CARCINOMA (HCC)[] | |
| ADVANCED RESEARCHES | Search for Effective Serum Tumor Markers for Early Diagnosis of Hepatocellular Carcinoma Associated with Hepatitis C[] |
| Life Sci | Selenium nanoparticles overcomes sorafenib resistance in thioacetamide induced hepatocellular carcinoma in rats by modulation of mTOR, NF-κB pathways and?…[Pubmed:35640776] |
